Peptide Therapeutics Market Report H1 2026: 8 Billion and Counting
The global peptide therapeutics market crossed 8 billion in 2025, sustained by the extraordinary commercial performance of GLP-1 receptor agonists and a deepening pipeline of candidates targeting metabolic disease, oncology, and rare disorders. Here is what the first-half 2026 data tell us about the industry’s trajectory.
The GLP-1 Juggernaut
Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) together generated 8.7 billion in 2025 revenue, representing 67% of the total peptide market. Novo Nordisk’s oral semaglutide formulation (Rybelsus) added .2 billion, validating the oral peptide delivery route that many had dismissed as commercially unviable. The GLP-1 class is on pace to exceed 0 billion in 2026 as manufacturing capacity expands — Novo Nordisk alone has committed 6.5 billion to new production facilities in Denmark, France, and the United States.
Pipeline Depth
As of June 2026, there are 212 peptide-based drug candidates in active clinical development (Phase I–III), up from 168 in 2023. Oncology has overtaken metabolic disease as the most active therapeutic area by number of candidates (78 vs. 54), driven by peptide-drug conjugates (PDCs) and neoepitope-targeting cancer vaccines. Notable PDC programs include Bicycle Therapeutics’ BT8009 (Nectin-4-targeting, Phase II/III) and Novartis’ 177Lu-PSMA-617 follow-ons.
The rare disease segment, while smaller in patient numbers, commands premium pricing: peptide drugs for rare indications carry a median annual cost of 80,000, compared to ,200 for metabolic peptides. This pricing dynamic is attracting venture investment into niche peptide programs.
Manufacturing Capacity Crunch
The industry’s growth is constrained not by demand but by supply. Global SPPS manufacturing capacity is estimated at 8.2 metric tons per year (peptide API), with Novo Nordisk and Eli Lilly consuming approximately 40% of that capacity for GLP-1 production alone. Contract development and manufacturing organizations (CDMOs) — led by Bachem, PolyPeptide Group, and CordenPharma — are investing over billion in capacity expansion through 2028. Bachem’s new Swiss facility (operational Q1 2026) added 1.2 metric tons of annual capacity, and the company has announced a further 2.0 metric ton expansion in California.
Investment and M&A
Peptide-focused biotech raised .7 billion in venture capital and public offerings in H1 2026, on pace to exceed 2025’s record of .1 billion. M&A activity has been concentrated in the PDC space: Merck’s .9 billion acquisition of PeptiDream’s oncology pipeline in March 2026 was the largest peptide deal of the half. The macrocycle platform companies — PeptiDream, Bicycle Therapeutics, and Circle Pharma — have emerged as the most sought-after acquisition targets.
The market is maturing from a single-class story (GLP-1) to a multi-pillar growth narrative spanning oncology, rare disease, and antimicrobial applications. The question is no longer whether peptides will be a major therapeutic class, but how quickly manufacturing capacity can scale to meet demand.